Patient Characteristics
| Characteristic | Group 1 | Group 2 |
|---|---|---|
| Total patients (n) | 23 | 34 |
| Sex (n) | ||
| Male | 15 | 18 |
| Female | 8 | 16 |
| Age (y) | ||
| Range | 30–76 | 30–78 |
| Average | 52 | 51 |
| Symptomatic patients before PRRT (n) | 23 | 34 |
| Prior therapy (n) | ||
| Chemotherapy | 9 | 6 |
| Octreotide analog | 5 | 7 |
| Primary site (n) | ||
| Pancreatic | 12 | 20 |
| Duodenal | 4 | 8 |
| Jejunal | 1 | 4 |
| Ileal | 6 | 2 |
| MIB-1 index | ||
| Range | 1%–15% | 1%–25% |
| Median | 3% | 4% |
| Primary tumor size before PRRT (cm) | ||
| Range | 3.5–11 | 4–12 |
| Average | 5.8 | 6 |
| Liver metastasis size before PRRT (cm) | ||
| Range | — | 0.8–5.6 |
| Average | — | 3 |
| Cumulative 177Lu-DOTATATE dose | ||
| Range | 14.8–40.7 GBq (400–1,100 mCi) | 14.8–40.7 GBq (400–1,100 mCi) |
| Average | 22.2 GBq (600 mCi) | 27.45 GBq (742 mCi) |
| PRRT cycles (n) | ||
| Range | 2–5 | 2–5 |
| Average | 4 | 4 |